Authors : Bill E. Cham
Abstract: It is now established that solasodine rhamnosyl glycosides (BEC) are antineoplastics. Specificity of BEC to interact with particular receptors on tumour cells relative to normal cells and the involvement of the sugar rhamnose, conjugated to the glycoalkaloids BEC, as a key molecule to gain entry into cancer cells but not normal cells has been established. Once the BEC-receptor is inside the cell by the receptor-mediated endocytosis process, the complex is eventually taken up by the lysosomes. BEC then induces the lysosome to rupture causing immediate cancer cell death by apoptosis. It is now accepted that BEC formulated in a topical cream is effective for treating non-melanoma skin cancers Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). Previous studies have described the efficacy of BEC on non-melanoma skin cancers that approximate lesion sizes of the general population. In this study, large non-melanoma skin cancers were treated with BEC as well as non-melanoma skin cancers located in areas of the body that are considered difficult to treat by any existing modality. Eight patients with BCCs and 11 patients with SCCs were treated and after treatment, were followed-up for at least 5 years. The results indicate that BEC can successfully dispose of large and difficult to treat BCCs and SCCs. Furthermore, the results demonstrate that the cosmetic effect after BEC therapy is superior to other treatment methods.
Bill E. Cham , 2007. Solasodine Rhamnosyl Glycosides in a Cream Formulation is Effective for Treating Large and Troublesome Skin Cancers . Research Journal of Biological Sciences, 2: 749-761.